HK1156533A1 - Controlled release corticosteroid compositions and methods for the treatment of otic disorders - Google Patents

Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Info

Publication number
HK1156533A1
HK1156533A1 HK11110956.8A HK11110956A HK1156533A1 HK 1156533 A1 HK1156533 A1 HK 1156533A1 HK 11110956 A HK11110956 A HK 11110956A HK 1156533 A1 HK1156533 A1 HK 1156533A1
Authority
HK
Hong Kong
Prior art keywords
treatment
methods
controlled release
otic disorders
corticosteroid compositions
Prior art date
Application number
HK11110956.8A
Other languages
English (en)
Inventor
Jay Lichter
Benedikt Vollrath
Andrew M Trammel
Sergio G Durón
Fabrice Piu
Luis A Dellamary
Qiang Ye
Carl Lebel
Michael Christopher Scaife
Jeffrey P Harris
Original Assignee
Otonomy Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41319223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1156533(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0823378A external-priority patent/GB2459910B/en
Application filed by Otonomy Inc, Univ California filed Critical Otonomy Inc
Publication of HK1156533A1 publication Critical patent/HK1156533A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
HK11110956.8A 2008-05-14 2011-10-14 Controlled release corticosteroid compositions and methods for the treatment of otic disorders HK1156533A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US12771308P 2008-05-14 2008-05-14
US6042508P 2008-06-10 2008-06-10
US7458308P 2008-06-20 2008-06-20
US8245008P 2008-07-21 2008-07-21
US8794008P 2008-08-11 2008-08-11
US9438408P 2008-09-04 2008-09-04
US9524808P 2008-09-08 2008-09-08
US10111208P 2008-09-29 2008-09-29
US14003308P 2008-12-22 2008-12-22
GB0823378A GB2459910B (en) 2008-04-21 2008-12-22 Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders
PCT/US2009/003066 WO2009139924A2 (en) 2008-05-14 2009-05-14 Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Publications (1)

Publication Number Publication Date
HK1156533A1 true HK1156533A1 (en) 2012-06-15

Family

ID=41319223

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11110956.8A HK1156533A1 (en) 2008-05-14 2011-10-14 Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Country Status (15)

Country Link
US (9) US8030297B2 (xx)
EP (1) EP2303227B1 (xx)
JP (3) JP5551685B2 (xx)
KR (2) KR101534422B1 (xx)
CN (2) CN102026623B (xx)
AU (1) AU2009246870B2 (xx)
BR (1) BRPI0912482A2 (xx)
CA (1) CA2723458C (xx)
HK (1) HK1156533A1 (xx)
IL (2) IL208806A (xx)
MX (1) MX2010012397A (xx)
MY (1) MY161021A (xx)
RU (2) RU2469726C2 (xx)
WO (1) WO2009139924A2 (xx)
ZA (1) ZA201007482B (xx)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130079749A1 (en) * 2007-08-29 2013-03-28 Advanced Bionics, Llc Modular Drug Delivery System for Minimizing Trauma During and After Insertion of a Cochlear Lead
WO2009108626A2 (en) 2008-02-25 2009-09-03 Eyegate Pharma S.A.S. Enhanced delivery of a therapeutic to ocular tissues through iontophoresis
EP2278999A4 (en) 2008-04-21 2015-04-22 Otonomy Inc EARLY TREATMENT FORMULATIONS FOR THE TREATMENT OF EARLY DISEASES AND DRESSES
EP2303227B1 (en) 2008-05-14 2021-10-06 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8648119B2 (en) * 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
CA2730847A1 (en) * 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8399018B2 (en) * 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
JP5421366B2 (ja) * 2008-07-21 2014-02-19 オトノミ―，インク． 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
EP2344151A4 (en) 2008-10-22 2012-04-18 House Ear Inst THERAPEUTIC AND / OR PROPHYLACTIC TREATMENT OF INTERNAL EAR PATHOLOGIES BY MODULATION OF THE METABOTROPIC GLUTAMATE RECEPTOR
JP6013736B2 (ja) * 2008-12-22 2016-10-25 オトノミ—，インク． 耳の障害の処置のための耳感覚細胞モジュレータ組成物の制御放出及びその方法
US20140076336A1 (en) * 2009-09-17 2014-03-20 Ascentia Health, Inc. Ear insert for relief of tmj discomfort and headaches
BR112012007473A2 (pt) * 2009-10-02 2019-05-07 Foamix Ltd composições tópicas de tetraciclina e respectivo método de uso
EP3508197A1 (en) * 2009-10-21 2019-07-10 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
JP6012112B2 (ja) * 2011-02-18 2016-10-25 オトノミ—，インク． 薬物により誘発される耳毒性の予防又は回復
EP2734557B1 (en) * 2011-07-20 2022-09-07 UroGen Pharma Ltd. Production of thermoreversible hydrogels for therapeutic applications
US10471010B2 (en) * 2011-11-04 2019-11-12 Enceladus Pharmaceuticals B.V. Liposomal corticosteroids for treatment of inflammatory disorders in humans
WO2013106230A1 (en) 2012-01-10 2013-07-18 Entrx LLC Otic formulations, methods and devices
JP2015527398A (ja) 2012-09-07 2015-09-17 マサチューセッツ アイ アンド イヤー インファーマリー 聴覚喪失治療
CN104822965B (zh) 2012-10-12 2017-11-28 利滕斯汽车合伙公司 通过环形传动构件由mgu或马达辅助或起动的发动机所使用的隔离器
US9849126B2 (en) 2013-01-03 2017-12-26 Entrx LLC Sterile otic formulations
NZ709620A (en) * 2013-01-23 2020-07-31 Semnur Pharmaceuticals Inc Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
ES2773310T3 (es) * 2013-02-28 2020-07-10 Anida Pharma Inc Métodos para tratamiento de la ototoxicidad
ES2727714T3 (es) * 2013-04-25 2019-10-18 Seachaid Pharmaceuticals Inc Composiciones de cefepima orales y uso de las mismas
CN105530867B (zh) 2013-08-21 2018-11-13 传感技术股份有限公司 用于生物感测分析物的体内保护的药物洗脱
CA2921816A1 (en) 2013-08-27 2015-03-05 Otonomy, Inc. Treatment of pediatric otic disorders
CN103751779A (zh) * 2014-02-25 2014-04-30 中国农业科学院上海兽医研究所 O型口蹄疫多肽的泊洛沙姆凝胶佐剂
CN104644545A (zh) * 2015-02-27 2015-05-27 苏州丝美特生物技术有限公司 一种治疗内耳疾病的控释缓释丝素蛋白凝胶制剂
KR101628707B1 (ko) * 2014-05-29 2016-06-10 한남대학교 산학협력단 난청 치료용 약물 전달 시스템 및 이의 제조방법
US20170216439A1 (en) * 2014-07-29 2017-08-03 Otonomy, Inc. Otic formulations for the treatment of ceruminosis
TWI674899B (zh) 2015-01-21 2019-10-21 美商桑紐爾製藥公司 醫藥配方
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
AU2016298307A1 (en) 2015-07-28 2018-02-15 Otonomy, Inc. TrkB or TrkC agonist compositions and methods for the treatment of OTIC conditions
US20170196802A1 (en) 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long Acting Injectable Formulations
WO2018193423A1 (en) * 2017-04-21 2018-10-25 Ferring B.V. Oral pharmaceutical compositions of corticosteroids
DK3641728T3 (da) * 2017-06-23 2021-06-07 Salvat Lab Sa En olie-i-vand-nanoemulsionssammensætning af clobetasol
WO2019066505A1 (ko) * 2017-09-29 2019-04-04 주식회사 엘지화학 히알루론산 기반 하이드로겔 약제학적 안정화 조성물 및 그 제조방법
KR20190038368A (ko) * 2017-09-29 2019-04-08 주식회사 엘지화학 히알루론산 기반 하이드로겔 약제학적 안정화 조성물 및 그 제조방법
CN107823636A (zh) * 2017-12-14 2018-03-23 阜阳市平衡医疗保健器械有限公司 一种治疗耳鸣的药物
CN108403628B (zh) * 2018-05-21 2021-01-08 北京和舆医药科技有限公司 一种地塞米松磷酸钠注射剂
WO2020092897A1 (en) 2018-11-02 2020-05-07 Senseonics, Incorporated Drug eluting matrix on analyte indicator
US20220062498A1 (en) * 2018-12-21 2022-03-03 Qmark Medical Inc. Hydrogel composition for mucosal lifting procedures within lumenal anatomical structures
US20200214976A1 (en) * 2019-01-09 2020-07-09 Spiral Therapeutics, Inc. Self-gelling solutions for administration of therapeutics to the inner ear
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
KR102425971B1 (ko) * 2020-06-02 2022-07-28 충남대학교산학협력단 덱사메타손 및 소듐 카프르산을 포함하는 내이 전달용 조성물
JPWO2022065404A1 (xx) * 2020-09-25 2022-03-31

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
IT1251151B (it) * 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
EP0551626A1 (en) 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ATE189772T1 (de) * 1993-04-16 2000-03-15 Wakamoto Pharma Co Ltd Unter wärmeeinwirkung reversibel gelierende medizinische zusammensetzung auf wasserbasis
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
WO1995015152A1 (fr) 1993-11-30 1995-06-08 Zenichi Ogita Preparation a usage externe
JP3696265B2 (ja) 1994-02-04 2005-09-14 日本オルガノン株式会社 点鼻液剤
DE69524398T2 (de) 1994-04-08 2002-07-18 Atrix Lab Inc Flüssige mittel zur wirkstoffabgabe
ATE342295T1 (de) 1995-07-28 2006-11-15 Genzyme Corp Biologische abbaubare multiblokhydrogene und ihre verwendung wie trägerstoffe fur kontrollierte freisetzung pharmakologisch activen werstoffe und gewebekontaktmaterialen
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
WO1997038698A1 (en) 1996-04-18 1997-10-23 University Technology Corporation Methods for treating middle and inner ear disorders
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
NL1004214C2 (nl) * 1996-10-07 1998-04-10 Avebe Coop Verkoop Prod Toepassing van gemodificeerd zetmeel als middel voor het vormen van een thermoreversibele gel.
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20010006944A1 (en) 1997-10-22 2001-07-05 Jens Ponikau Methods and materials for treating and preventing inflammation of mucosal tissue
DE19748763A1 (de) 1997-11-05 1999-05-06 Hans Peter Zenner Verwendung von Vasopressin-Antagonisten
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6177434B1 (en) 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6649621B2 (en) 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
EP1039932A1 (en) 1997-12-23 2000-10-04 Alliance Pharmaceutical Corporation Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
EP1109563A4 (en) * 1998-08-04 2009-07-22 Madash Llp HEAT-SENSITIVE HYDROGELS WITH MODIFIED TERMINATION
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
EP1158957A4 (en) 1999-02-24 2004-12-15 Dong Wha Pharm Ind Co Ltd LIQUID SUPPOSITORY COMPOSITION FOR DICLOFENAC SODIUM
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
DE60006262T2 (de) * 1999-09-24 2004-05-13 Alcon, Inc. Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
MXPA02008966A (es) 2000-03-14 2003-02-12 Alcon Inc Viscoelasticos para uso en cirugia del oido medio.
WO2001072298A1 (en) * 2000-03-27 2001-10-04 The General Hospital Corporation Treatments for immune-mediated ear disorders
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
DE10346940B3 (de) 2003-10-06 2005-06-16 Schering Ag Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
SE0100158D0 (sv) 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
US20060269602A1 (en) 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
TWI324925B (en) 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
US6488952B1 (en) 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
WO2003026671A1 (en) * 2001-09-21 2003-04-03 Alcon, Inc. Method of treating middle ear infections
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
DE10162593A1 (de) 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen
US20030229333A1 (en) 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
WO2004039328A2 (en) * 2002-10-29 2004-05-13 Oregon Health & Science University Fludrocortisone treatment for hearing loss
US20040101506A1 (en) 2002-11-25 2004-05-27 Fust Charles A. Composition for the prevention and treatment of inflammation of the ear
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2004093870A1 (en) 2003-03-20 2004-11-04 Pharmacia Corporation Treatment and prevention of otic disorders
US7700086B2 (en) 2003-11-06 2010-04-20 Pluromed, Inc. Internal clamp for surgical procedures
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
US8268866B2 (en) * 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
CA2568028A1 (en) 2004-05-24 2005-12-08 Auris Medical, Llc. Combined otic aspirator and medication dispenser
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
MX2007002462A (es) 2004-09-03 2007-10-10 Piedmont Pharmaceuticals Llc Metodo para el tratamiento de transmembrana y prevencion de la otitis media.
JP2006111585A (ja) 2004-10-15 2006-04-27 Mebiol Kk 徐放性組成物およびその徐放方法
CA2594963A1 (en) * 2005-01-24 2006-07-27 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
CN101137359B (zh) 2005-03-10 2011-01-12 3M创新有限公司 治疗耳感染的方法
BRPI0606283A2 (pt) * 2005-03-16 2009-06-09 Elan Pharma Int Ltd formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula
JP2008534530A (ja) * 2005-03-29 2008-08-28 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 活性成分放出に関して調節作用を有する物質を有するペレットを含有している多粒子薬剤形
EP1893174A2 (en) 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
KR101041843B1 (ko) 2005-07-30 2011-06-17 삼성엘이디 주식회사 질화물계 화합물 반도체 발광소자 및 그 제조방법
US20070048338A1 (en) 2005-08-26 2007-03-01 Ladd Byron S Compositions and methods for surface treatment in medical and surgical procedures
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
CN101272772A (zh) 2005-09-26 2008-09-24 皮埃蒙特医药品有限公司 使用化学渗透促进剂促进跨膜药物输送到中耳治疗和预防中耳炎的方法
EP1931388A4 (en) 2005-09-26 2010-12-15 Piedmont Pharmaceuticals Llc METHODS OF TREATING AND PREVENTING AVERAGE OTITIS THROUGH NON-IONIC SURFACTANTS TO FACILITATE DELIVERY OF TRANSMEMBRANE DRUG IN THE MIDDLE EAR
EA017264B1 (ru) * 2005-09-28 2012-11-30 Аурис Медикаль Аг Применение композиции арилциклоалкиламида для получения лекарственного препарата для лечения нарушения внутреннего уха
US20070110788A1 (en) 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
FR2894585B1 (fr) 2005-12-14 2012-04-27 Rhodia Recherches Et Tech Copolymere comprenant des unites zwitterioniques et d'autres unites, composition comprenant le copolymere, et utilisation
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
WO2008001341A1 (en) 2006-06-27 2008-01-03 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
WO2008049196A1 (en) * 2006-10-27 2008-05-02 Iomedix Development International Srl Composition for improving blood cholesterol levels
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
CN105251035A (zh) 2006-12-11 2016-01-20 健赞公司 灌注器官止血法
EP2150244A1 (en) * 2007-04-23 2010-02-10 House Ear Institute Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7
US7795231B2 (en) 2007-10-04 2010-09-14 Insite Vision Incorporated Concentrated aqueous azalide formulations
EP2278999A4 (en) 2008-04-21 2015-04-22 Otonomy Inc EARLY TREATMENT FORMULATIONS FOR THE TREATMENT OF EARLY DISEASES AND DRESSES
EP2303227B1 (en) 2008-05-14 2021-10-06 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8822410B2 (en) * 2008-05-19 2014-09-02 Children's Medical Center Corporation Tympanic membrane permeating ear drops and uses thereof
US8648119B2 (en) * 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) * 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
CA2730847A1 (en) * 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CN104352429B (zh) 2008-07-21 2018-05-18 奥德纳米有限公司 用于治疗耳部病症的受控释放抗微生物组合物和方法
US8399018B2 (en) * 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
JP5421366B2 (ja) * 2008-07-21 2014-02-19 オトノミ―，インク． 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8496957B2 (en) * 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CN101664381A (zh) 2009-08-21 2010-03-10 天津生机集团股份有限公司 治疗奶牛乳房炎的原位凝胶缓释制剂的制备方法
EP3508197A1 (en) 2009-10-21 2019-07-10 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
ES2369101B2 (es) 2010-05-07 2012-08-02 Universidade De Santiago De Compostela Sistema farmacéutico acuoso para la administración de fármacos en las uñas.

Also Published As

Publication number Publication date
MX2010012397A (es) 2011-03-15
CN102026623B (zh) 2013-08-14
IL208806A0 (en) 2011-01-31
IL208806A (en) 2016-02-29
ZA201007482B (en) 2012-01-25
US8680082B2 (en) 2014-03-25
CN103417472B (zh) 2018-01-02
JP6014069B2 (ja) 2016-10-25
MY161021A (en) 2017-03-31
US20100009952A1 (en) 2010-01-14
IL244103A0 (en) 2016-04-21
AU2009246870A1 (en) 2009-11-19
EP2303227B1 (en) 2021-10-06
CA2723458A1 (en) 2009-11-19
US20140364403A1 (en) 2014-12-11
US8680083B2 (en) 2014-03-25
JP5551685B2 (ja) 2014-07-16
WO2009139924A2 (en) 2009-11-19
US8828980B2 (en) 2014-09-09
US9511020B2 (en) 2016-12-06
US20150313838A1 (en) 2015-11-05
RU2010150863A (ru) 2012-06-20
JP2011529854A (ja) 2011-12-15
US20180110727A1 (en) 2018-04-26
US20110319375A1 (en) 2011-12-29
JP2014101392A (ja) 2014-06-05
EP2303227A4 (en) 2012-10-31
KR101477329B1 (ko) 2014-12-29
RU2012139802A (ru) 2014-03-27
KR101534422B1 (ko) 2015-07-09
US20110008456A1 (en) 2011-01-13
RU2469726C2 (ru) 2012-12-20
CA2723458C (en) 2014-01-28
CN103417472A (zh) 2013-12-04
KR20100135321A (ko) 2010-12-24
BRPI0912482A2 (pt) 2020-08-18
US20110319374A1 (en) 2011-12-29
EP2303227A2 (en) 2011-04-06
US9744126B2 (en) 2017-08-29
WO2009139924A3 (en) 2010-04-01
US8030297B2 (en) 2011-10-04
AU2009246870B2 (en) 2013-08-01
US8546363B2 (en) 2013-10-01
US20110319373A1 (en) 2011-12-29
US8658626B2 (en) 2014-02-25
JP2016153423A (ja) 2016-08-25
KR20130100017A (ko) 2013-09-06
US20110319377A1 (en) 2011-12-29
CN102026623A (zh) 2011-04-20

Similar Documents

Publication Publication Date Title
HK1156533A1 (en) Controlled release corticosteroid compositions and methods for the treatment of otic disorders
IL210720A0 (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
HRP20182135T1 (hr) Pripravci za i postupci liječenja poremećaja povezanih s ige
IL258730A (en) Preparations and methods for the treatment of microbial disorders
EP2120580A4 (en) COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
GB201001047D0 (en) Methods and compositions for the treatment of neurological disorders
IL209032A0 (en) Compositions and methods for treating digestive disorders
HUE061548T2 (hu) Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
WO2011049960A9 (en) Compositions and methods for the treatment of sinonasal disorders
EP2552433A4 (en) COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
GB2459910B (en) Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders
EP2299976A4 (en) SELF-CONTROLLED RELEASE SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR TREATING OTIC DISORDERS
EP2309858A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
PL2300614T3 (pl) Sposoby i kompozycje do leczenia zaburzeń mitochondrialnych
EP2142566A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP2370087A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID RETENTION DISORDERS
GB0907065D0 (en) Anti-apoptotic composition and methods for the treatment of otic disorders
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
IL210933A0 (en) Compositions and methods for treating inflammatory disorders
AU2007906680A0 (en) Methods and compositions for the treatment of phosphatase-related disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210518